Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects

NCT02931214 is registered in ClinicalTrials.gov with GlycoMimetics Incorporated as lead sponsor.

NCT NCT02931214
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02931214 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GMI-1359 in Healthy Adult Subjects
Lead sponsor
GlycoMimetics Incorporated
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2016
Completion date
November 30, 2018
Enrollment
58 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy